MCE products for research use only. We do not sell to patients.

Valinomycin

MCE China：Valinomycin

Brand：MedChemExpress (MCE)

Cat. No.HY-N6693

CAS：2001-95-8

Synonyms：NSC 122023

Purity：98.63%

Storage：Sealed storage, away from moisture Powder -80°C 2 years -20°C 1 year *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Shipping：Room temperature in continental US; may vary elsewhere.

Description：Valinomycin is a potassium-specific ionophore, the valinomycin-K+ complex can be incorporated into biological bilayer membranes with the hydrophobic surface of valinomycin, destroys the normal K+ gradient across the membrane, and as a result kills the cells, incorporating into liposomes can significantly reduces the cytotoxicity and enhances the targeting effect. Valinomycin exhibits antibiotic, antifungal, antiviral, antitumor and insecticidal efficacy, thus can be used for relevant research.

In Vitro：Lipo-Valinomycin (1-100 μM, 24 h) suppresses the viability of HepG2 significantly in a concentration-dependent manner[2]. Lipo-Valinomycin (15 μM, 12 h) degrades the mitochondrial membrane potential and induces apoptosis (23%) of HepG2[2]. 1.19 Valinomycin bioactivities[1] Bioactivity Target Efficacy Antibacterial Streptococcus pyogenes MIC 0.02 µg/mL Clostridium sporogenes MIC 8 µg/mL Enterococcus faecalis MIC 0.39–0.78 µg/disk Streptococcus pneumoniae MIC 0.39–0.78 µg/disk Micrococcus luteus MIC 25–50 µg/disk Antifungal Candida albicans MIC 0.39–0.78 µg/disk Cryptococcus neoformans MIC 50–100 µg/disk Phytophthora capsici IC50 15.9 µg/mL Botrytis cinerea MIC 4 µg/mL Magnaporthe grisea MIC 4 µg/mL Candida albicans MIC 32 µg/mL Colletotrichum gloeosporioides MIC 256 µg/mL Rhizoctonia solani MIC 256 µg/mL Penicillium verrucosum IC50 0.005 ng/mL Antiviral SARS-CoV EC50 0.85 µM PRRSV IC50 24 nM RSV IC50 0.0015 µM MERS-CoV IC50 84 nM HCoV-OC43 EC50 4.43 µM HCoV-NL63 EC50 1.89 µM MHV-A59 EC50 6.78 µM LACV IC50 588 nM RVFV MP-12 IC50 41 nM HRV2 IC50 610 nM CVB3 IC50 971 nM ZIKV IC50 78 nM KEYV IC50 156 nM HCoV-229E IC50 67 nM LASV EC50 0.61 µM LCMV EC50 0.15 µM Antitumor Human ovarian tumor cells CaOV-3 IC50 0.1 nM Murine P388 leukemia cancer cells GI50 0.019 µg/mL Human ovary OVCAR-3 tumor cells GI50 0.19 ng/mL Brain SF-295 tumor cells GI50 0.35 ng/mL Renal A-498 carcinoma cells GI50 1.9 ng/mL Lung NCI-H460 cancer cells GI50 0.21 ng/mL Colon KM20L2 carcinoma cells GI50 0.27 ng/mL Melanoma SK-MEL-5 cancer cells GI50 0.26 ng/mL Rat C6 glioma cells IC50 0.4 µM Human A2780 ovarian carcinoma cells IC50 2.18 µM Human MCF-7 breast carcinoma cells IC50 1.77 µM Human HepG2 hepatocellular carcinoma cells IC50 0.0008 µM Human U251 glioma cells IC50 7.6 nM

In Vivo：Lipo-Valinomycin (1-40 μg/g, i.v., every 2 days for 16 d) inhibits HepG2 tumor growth in nude mice[2].

Hot selling product：BSJ-04-132  | Selinexor  | Olaratumab  | CX516  | Ibuprofen  | BCECF-AM  | Fumitremorgin C  | Anidulafungin  | CDFI  | Rosmarinic acid

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References：

[1]. Huang S, et al. The Nonribosomal Peptide Valinomycin: From Discovery to Bioactivity and Biosynthesis. Microorganisms. 2021，9(4):780.  [Content Brief]

[2]. Zhang QW, et al. RETRACTED: Liposomal valinomycin mediated cellular K+ leak promoting apoptosis of liver cancer cells. J Control Release. 2021，337:317-328.  [Content Brief]